GlassScriptPhysician profile
Bruce Wade Cline
NPI 1316926371
$6,781.55
in general payments reported to CMS, 2019-2025
23 companies · $891 in 2025
The $891 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $516 · 2021: $936 · 2022: $1,169 · 2023: $1,152 · 2024: $830 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Entertainment: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.43 |
| Entertainment | $315.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,756.08 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $862.14 | 2019-2021 | |
| Optos, INC. | $708.02 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $574.12 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Coopervision INC. | $558.94 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Allergan, INC. | $416.45 | 2019-2021 | |
| Notal Vision, INC. | $263.89 | 2022 | |
| Lkc Technologies, INC. | $256.49 | 2024-2025 | |
| Abb Con-Cise Optical Group LLC | $163.87 | 2021-2024 | Contact Lens, Spectacle Lenses |
| Biotissue Holdings INC. | $162.59 | 2019-2025 | |
| Abbvie INC. | $153.65 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $133.65 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $124.98 | 2021 | |
| Horizon Therapeutics Plc | $124.97 | 2023 | Tepezza |
| Maculogix, INC. | $122.11 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $71.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.98 | 2020-2023 | |
| Dompe US, INC. | $60.93 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $23.95 | 2022 | |
| Shire North American Group INC | $23.10 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.89 | 2019 | |
| Sight Sciences, INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.